

(b) a unique fragment of the nucleotide sequence set forth as nucleotides 1-2442 of SEQ ID NO:43 between 12 and 2441 nucleotides in length, which encodes a portion of SEQ ID NO:44, wherein the portion of SEQ ID NO:44 is at least 8 amino acids in length, and

(c) complements of (a) and (b), wherein the unique fragment excludes nucleic acid molecules completely composed of the nucleotide sequences of GenBank accession numbers U89672 or AA213817.

40.(twice amended) A composition comprising:

an antisense nucleic acid which binds *in vitro* to a tumor associated nucleic acid which hybridizes under stringent conditions to a nucleic acid molecule having a nucleotide sequence selected from the group consisting of SEQ ID NO:38 and SEQ ID NO:43, and reduces the expression of the tumor associated nucleic acid *in vitro*.

41.(thrice amended) A kit for detecting the presence of the expression of a tumor associated polypeptide precursor which encodes a portion of SEQ ID NO:39, comprising a first isolated nucleic acid molecule consisting of a 12-32 nucleotide contiguous segment of SEQ ID NO:38, and a second isolated nucleic acid molecule consisting of a 12-32 nucleotide contiguous segment of the complement of SEQ ID NO:38, wherein the contiguous segments are nonoverlapping, and wherein the portion of SEQ ID NO:39 is at least 8 amino acids in length.

57.(amended) The kit of claim 41, wherein the first and the second isolated nucleic acid molecules are constructed and arranged to selectively amplify at least a portion of an isolated nucleic acid molecule comprising SEQ ID NO:38, wherein the portion of SEQ ID NO:38 is at least 24 nucleotides in length.

58.(amended) The kit of claim 43, wherein the first and the second isolated nucleic acid molecules are constructed and arranged to selectively amplify at least a portion of an isolated nucleic acid molecule comprising SEQ ID NO:43, wherein the portion of SEQ ID NO:38 is at least 24 nucleotides in length.